These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9633842)

  • 61. [An overview of new prognostic factors for ovarian cancer].
    Shimizu Y; Hasumi K
    Gan To Kagaku Ryoho; 1992 Jan; 19(1):40-7. PubMed ID: 1729959
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prognostic importance of histologic type in ovarian carcinoma.
    Gallager HS
    Natl Cancer Inst Monogr; 1975 Oct; 42():13-4. PubMed ID: 1234630
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Progress in the management of ovarian cancer at the First Department of Obstetrics and Gynecology, University of Vienna, since 1955.
    Gitsch E; Salzer H
    Verh K Acad Geneeskd Belg; 1993; 55(2):145-9. PubMed ID: 8480450
    [No Abstract]   [Full Text] [Related]  

  • 64. Prognostic indices in ovarian cancer. Their significance in treatment planning.
    Swenerton KD
    Acta Obstet Gynecol Scand Suppl; 1992; 155():67-74. PubMed ID: 1502892
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Staging and differentiated grading are the factors influencing mortality in ovarian cancer].
    Sigurdsson K; Alm P; Gullberg B; Johnsson JE; Tropé C
    Lakartidningen; 1984 Jun; 81(23):2354-7. PubMed ID: 6738240
    [No Abstract]   [Full Text] [Related]  

  • 66. Ovarian cancer: should we be managing patients with good and bad prognostic factors in the same manner?
    Eisenhauer EA; Gore M; Neijt JP
    Ann Oncol; 1999; 10 Suppl 1():9-15. PubMed ID: 10219447
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Use of automated programs for comprehensive prognostic evaluation of individual adaptive potential].
    Kazin EM; Kuraev GA; Shorin IuP; Lur'e SB
    Fiziol Cheloveka; 1993; 19(3):88-93. PubMed ID: 8354456
    [No Abstract]   [Full Text] [Related]  

  • 68. Evolving Aspects of Prognostic Factors for Pediatric Cancer.
    Kourti M; Hatzipantelis E
    Diagnostics (Basel); 2023 Nov; 13(23):. PubMed ID: 38066756
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The Role of Perioperative C-Reactive Protein in Predicting the Prognosis of Epithelial Ovarian Carcinoma.
    Pan Q; Wei M; Lu M; Xu Y; Xie X; Li X
    Cancer Manag Res; 2023; 15():233-243. PubMed ID: 36873254
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Downregulated Salt-inducible Kinase 3 Expression Promotes Chemoresistance in Serous Ovarian Cancer via the ATP-binding Cassette Protein ABCG2.
    Liang YL; Wu CH; Kang CY; Lin CN; Shih NY; Lin SH; Chen YC; Hsu KF
    J Cancer; 2019; 10(24):6025-6036. PubMed ID: 31762812
    [No Abstract]   [Full Text] [Related]  

  • 71. Age-related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer.
    Yoshikawa K; Fukuda T; Uemura R; Matsubara H; Wada T; Kawanishi M; Tasaka R; Kasai M; Hashiguchi Y; Ichimura T; Yasui T; Sumi T
    Mol Clin Oncol; 2018 Sep; 9(3):329-334. PubMed ID: 30112179
    [TBL] [Abstract][Full Text] [Related]  

  • 72. MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer.
    Xiao S; Zhang M; Liu C; Wang D
    Mol Genet Genomics; 2018 Oct; 293(5):1159-1167. PubMed ID: 29752546
    [TBL] [Abstract][Full Text] [Related]  

  • 73. NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib.
    Kankia IH; Khalil HS; Langdon SP; Moult PR; Bown JL; Deeni YY
    Oxid Med Cell Longev; 2017; 2017():1864578. PubMed ID: 29410730
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer.
    Liu Y; Chen S; Zheng C; Ding M; Zhang L; Wang L; Xie M; Zhou J
    BMC Cancer; 2017 Apr; 17(1):285. PubMed ID: 28431566
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Primary and metastatic ovarian cancer: Characterization by 3.0T diffusion-weighted MRI.
    Lindgren A; Anttila M; Rautiainen S; Arponen O; Kivelä A; Mäkinen P; Härmä K; Hämäläinen K; Kosma VM; Ylä-Herttuala S; Vanninen R; Sallinen H
    Eur Radiol; 2017 Sep; 27(9):4002-4012. PubMed ID: 28289938
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines.
    Kloudová K; Hromádková H; Partlová S; Brtnický T; Rob L; Bartůňková J; Hensler M; Halaška MJ; Špíšek R; Fialová A
    Oncotarget; 2016 Jul; 7(29):46120-46126. PubMed ID: 27323861
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer.
    Pchejetski D; Alfraidi A; Sacco K; Alshaker H; Muhammad A; Monzon L
    J Cancer Res Clin Oncol; 2016 Aug; 142(8):1659-71. PubMed ID: 26560874
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Public perception of risk-reducing salpingectomy for preventing ovarian cancer.
    Kang JH; Nam SH; Song T; Kim WY; Lee KW; Kim KH
    Obstet Gynecol Sci; 2015 Jul; 58(4):284-8. PubMed ID: 26217598
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Prognostic evaluation of preoperative serum C-reactive protein concentration in patients with epithelial ovarian cancer.
    Lu Y; Huang S; Li P; Chen B; Liu W; Chen Z; Yin F
    Exp Ther Med; 2015 May; 9(5):2003-2007. PubMed ID: 26136929
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Role of TWIST in Ovarian Epithelial Cancers.
    Kim K; Park EY; Yoon MS; Suh DS; Kim KH; Lee JH; Shin DH; Kim JY; Sol MY; Choi KU
    Korean J Pathol; 2014 Aug; 48(4):283-91. PubMed ID: 25214860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.